<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01799356</url>
  </required_header>
  <id_info>
    <org_study_id>Asicioglu03</org_study_id>
    <secondary_id>treatment</secondary_id>
    <secondary_id>treatment uPID</secondary_id>
    <nct_id>NCT01799356</nct_id>
  </id_info>
  <brief_title>Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul Bakirkoy Maternity and Children Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul Bakirkoy Maternity and Children Diseases Hospital</source>
  <brief_summary>
    <textblock>
      We aimed to compare efficacy and safety of combination therapy with oral ofloxacin, 400 mg
      twice daily, plus oral metronidazole, 500 mg twice daily, for 14 days, with moxifloxacin
      monotherapy, 400 mg once daily, for 14 days
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinically cure</measure>
    <time_frame>21 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiological cure</measure>
    <time_frame>21 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1303</enrollment>
  <condition>Pelvic Inflammatory Disease</condition>
  <arm_group>
    <arm_group_label>moxifloxacin Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment at uPID with moxifloxacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ofloxacin Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment at uPID with Ofloxacin plus metronidazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>daily 400 mg moksifloksasin</description>
    <arm_group_label>moxifloxacin Group</arm_group_label>
    <other_name>new generetaion flouroquinolon antibiotics</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ofloxacin</intervention_name>
    <description>daily 800 mg oflaksasin plus 1000 mg metronidazol treatment</description>
    <arm_group_label>Ofloxacin Group</arm_group_label>
    <other_name>floroquinolon antibiotics</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>daily 1000 mg metronidazol plus 800 mg oflaksasin treatment for uPID</description>
    <arm_group_label>Ofloxacin Group</arm_group_label>
    <other_name>anaerobic antibiotics</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women diagnosed uncomplicated PID

          2. Patients age are between 14 with 45

          3. Pelvic tenderness and vaginal discharge

        Exclusion Criteria:

          1. Urinary Tract Enfections

          2. Tubo-ovarian abscess and complicated PID

          3. Hıstory of antibiotics treatment

          4. Other pelvic pain causes

          5. Endometriosis

          6. Delivery,abortion and surgery within last months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kemal Gungorduk, md</last_name>
    <role>Study Chair</role>
    <affiliation>T.C.S.B. Kanıni Sultan Suleyman Training Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>T.C.S.B. İstanbul Training Research Hospital</name>
      <address>
        <city>Samatya</city>
        <state>Fatih</state>
        <zip>34180</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>T.C.S.B. Kanuni Sultan Suleyman Training Hospital</name>
      <address>
        <city>İstanbul</city>
        <state>Kucukcekmece</state>
        <zip>34280</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>T.C.S.B Mardin Women and Children Hospital</name>
      <address>
        <city>Mardin</city>
        <zip>47000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>T.C.S.B. Şişli Etfal Training Research Hospital</name>
      <address>
        <city>Şişli</city>
        <zip>34150</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Judlin P, Liao Q, Liu Z, Reimnitz P, Hampel B, Arvis P. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG. 2010 Nov;117(12):1475-84. doi: 10.1111/j.1471-0528.2010.02687.x. Epub 2010 Aug 18.</citation>
    <PMID>20716255</PMID>
  </results_reference>
  <results_reference>
    <citation>Boothby M, Page J, Pryor R, Ross JD. A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease. Int J STD AIDS. 2010 Mar;21(3):195-7. doi: 10.1258/ijsa.2009.009374.</citation>
    <PMID>20215625</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2013</study_first_submitted>
  <study_first_submitted_qc>February 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2013</study_first_posted>
  <last_update_submitted>August 27, 2013</last_update_submitted>
  <last_update_submitted_qc>August 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul Bakirkoy Maternity and Children Diseases Hospital</investigator_affiliation>
    <investigator_full_name>Osman Aşıcıoğlu</investigator_full_name>
    <investigator_title>Istanbul Sisli Etfal Training Research Hospital</investigator_title>
  </responsible_party>
  <keyword>Treatment, moksifloksasin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pelvic Inflammatory Disease</mesh_term>
    <mesh_term>Pelvic Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

